After years of dominating the obesity drug market, Danish pharmaceutical giant Novo Nordisk $NOVO-B.CO has revised its 2025 sales forecast downward, citing a surprising stagnation in U.S. demand for its flagship weight-loss medication, Wegovy. The updated guidance marks the end of a robust four-year growth trajectory that began with the drug’s market debut.